Home > Oncology > ASCO 2022 > CALYPSO: exploratory treatment options fail in ccRCC

CALYPSO: exploratory treatment options fail in ccRCC

Presented By
Prof. Thomas Powles, University of London, UK
ASCO 2022
Phase 2, CALYPSO
Although the 4 tested treatment regimens – durvalumab alone, or plus tremelimumab or savolitinib, or savolitinib alone – of the phase 2 CALYPSO trial appeared to be safe therapies in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), the primary efficacy endpoint was not met for any treatment regimen. The CALYPSO trial (NCT02819596) randomised 139 patients with vascular endothelial growth factor (VEGF) refractory ccRCC to one of four treatment arms: the PD-L1 inhibitor durvalumab alone (n=39); durvalumab plus the CTLA-4 inhibitor tremelimumab (n=39); durvalumab plus the MET inhibitor savolitinib (n=39); or savolitinib alone (n=19). Prof. Thomas Powles (University of London, UK), who presented the results of the trial, added that the savolitinib monotherapy arm was closed early, be...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on